A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: Case report

Neurosurgery

Volumn 60, Issue 6, 2007, Pages

  Smith, Edward R ^a,b   Manfredi, Michael ^a   Scott, R Michael ^a,b   Black, Peter M ^a,b   Moses, Marsha A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Brain tumor; Matrix metalloproteinase; Urine

Indexed keywords

BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; TUMOR MARKER;

ARTICLE; CASE REPORT; CRANIOPHARYNGIOMA; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RADIOGRAPHY; SCHOOL CHILD; TUMOR DIAGNOSIS; TUMOR RECURRENCE; URINALYSIS;

BIOLOGICAL MARKERS; CHILD; CRANIOPHARYNGIOMA; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS;

EID: 34249829865     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000255464.37634.3C     Document Type: Article

References (15)

1. Beliveau R, Delbecchi L, Beaulieu E, Mousseau N, Kachra Z, Berthelet F, Moumdjian R, Del Maestro R: Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Ann N Y Acad Sci 886:236-239, 1999.
2. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawu K, Thorpe P, Itobara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cel Biol 2:737-744, 2000.
3. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K: Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: A longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22:499-506, 2004.
4. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakapoulous G, Moses MA: Matrix metalloproteinase-9 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci 97:38884-38889, 2000.
5. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA: The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390-5395, 2005.
6. Harper J, Moses MA: Molecular regulation of tumor angiogenesis: Mechanisms and therapeutic implications, in Bignold LP (ed): Cancer: Cell Structures, Carcinogens and Genomic Instability. Basel, Switzerland, Birkhauser Verlag, 2006, pp 223-268.
7. Kunishio K, Okada M, Matsumoto Y, Nagao S: Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 20:39-45, 2003.
8. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B: Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 153:429-437, 1998.
9. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248:1408-1410, 1990.
10. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399, 1998.
11. Noha M, Yoshida D, Watanabe K, Teramoto A: Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: In vitro study. J Neurooncol 48:217-223, 2000.
12. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA: ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279:51323-51330, 2004.
13. Smith ER, Butler WE, Barker FG 2nd: Craniotomy for resection of pediatric brain tumors in the United States, 1988 to 2000: Effects of provider caseloads and progressive centralization and specialization of care. Neurosurgery 54:553-565, 2004.
14. Thier M, Roeb E, Breuer B, Bayer TA, Halfter H, Weis J: Expression of matrix metalloproteinase-2 in glial and neuronal tumor cell lines: Inverse correlation with proliferation rate. Cancer Lett 149:163-170, 2000.
15. Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258-37265, 2001.